Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 agonists for diabetes, with new data for Mounjaro on cardiovascular outcomes. The results of the SURPASS-CVOT trial showed ...
Large US law firm apologizes for AI errors in bankruptcy court filing Marking the latest collision of artificial intelligence with attorney ethics, a large U.S. law firm told a judge it was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback